ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Net Income
Bottom-line profit after all expenses, interest, and taxes.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$35.77M, compared with -$30.02M a year earlier. Trailing-twelve-month net income was -$135.21M.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$128.9M (+0.4%) for the fiscal year ending Dec 2026, a step up from the -1.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$35.77M-17.2% QoQ
- Last fiscal yearDec 2025
- -$129.47M-1.3% YoY
- LTMMar 2026
- -$135.21M-1.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -19.1% | -4.3% | +14.8 pp |
| 1 year | -1.3% | +0.4% | +1.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (129.47M) USD
- Year-over-year change
- -1.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.47M) | -1.3% |
| FY2024 | 2024-12-31 | (127.85M) | -27.0% |
| FY2023 | 2023-12-31 | (100.7M) | -13.0% |
| FY2022 | 2022-12-31 | (89.12M) | -13.2% |
| FY2021 | 2021-12-31 | (78.72M) | — |
Net Income vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 net income of -$135.21M is the 7th highest of the 11 companies compared; the peer median is -$122.79M.
- Its year-over-year change of -1.8% is the 3rd highest of 11, against a peer median of -21.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$27.16M | -34.7% | — | — | |
| LTM Mar 2026 | -$44.17M | -6.7% | — | — | |
| LTM Mar 2026 | -$70.36M | -26.1% | — | 44.8% | |
| LTM Sep 2026 | -$113.48M | -16.7% | — | — | |
| LTM Mar 2026 | -$114.48M | -47.3% | — | 529.7% | |
| LTM Mar 2026 | -$131.11M | -36.0% | — | — | |
| LTM Mar 2026 | -$135.21M | -1.8% | — | — | |
| LTM Mar 2026 | -$145.24M | -14.0% | — | — | |
| LTM Jun 2026 | -$149.83M | +26.2% | — | 88.2% | |
| LTM Mar 2026 | -$193.96M | -30.3% | — | 391.2% | |
| LTM Mar 2026 | -$243.25M | +26.6% | — | 112.0% | |
| Peer median (excluding ORIC) | -$122.79M | -21.4% | — | 112.0% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.03M | 1.11M | 1.22M |
| Gross Profit | 0 | 0 | (1.03M) | (1.11M) | (1.22M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 56.86M | 61.68M | 85.17M | 114.07M | 109.82M |
| Selling, General & Admin | 22.01M | 25.09M | 25.61M | 28.82M | 33.19M |
| Operating Expenses | 78.87M | 91.77M | 109.75M | 141.79M | 141.78M |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| EBITDA | (77.82M) | (85.8M) | (99.67M) | (126.74M) | (128.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (78.87M) | (91.77M) | (110.78M) | (142.9M) | (143M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 141K | 2.65M | 10.08M | 0 | 0 |
| Interest Expense | 0 | 2.65M | 0 | 0 | 0 |
| Other Income / Expenses | 156K | 2.65M | 10.08M | 15.05M | 13.54M |
| Income Before Tax | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| EPS (Diluted) | (2.07) | (2.25) | (1.96) | (1.83) | (1.47) |
| Weighted Avg Shares | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
| Weighted Avg Shares (Diluted) | 37.95M | 39.66M | 51.45M | 69.73M | 87.79M |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.